Life Science Insights 360 Podcasts

Life Science Insights360
  • 0.0 (0)
  • Life Sciences
  • Updated Daily

Welcome to Life Science Insights360, your go-to source for deep conversations with the innovators shaping the future of healthcare, biotech, and life sciences. Hosted by Senthil Karunanith, each episode dives into cutting-edge topics—from translational omics and therapeutic breakthroughs to strategic data insights, quality management, and real-world challenges in pharma, medtech, and diagnostics . Expect dynamic interviews with industry leaders—CEOs, scientists, strategists—who share real-world case studies and forward-thinking visions.

  1. Jul 9

    E29 - The Future of Clinical Research Sites | Jimmy Bechtel (CSSO, SCRS) | Life Science Insights

    In this episode of the Life Science Insights Podcast, we sit down with Jimmy Bechtel, Chief Strategy & Site Solutions Officer (CSSO) at the Society for Clinical Research Sites (SCRS), to explore the evolving landscape of clinical research and the critical role research sites play in advancing innovation, improving patient outcomes, and driving more efficient clinical trials.Jimmy shares his perspective on the challenges facing research sites today, the growing importance of site sustainability, and how technology, AI, and stronger collaboration between sponsors, CROs, and research sites are shaping the future of clinical research. We also discuss how patient-centric approaches, operational excellence, and digital transformation are redefining the clinical trial ecosystem.Key Topics DiscussedJimmy Bechtel's professional journey into clinical research and site managementThe meaning of site success in today's clinical trial environmentMajor operational challenges facing clinical research sitesThe growing importance of long-term site sustainabilityStrengthening collaboration between research sites, sponsors, and CROsLeveraging technology to improve site efficiency and reduce administrative burdenThe evolution of decentralized and hybrid clinical trialsStrategies for improving patient engagement and retentionAddressing workforce shortages in clinical researchThe impact of AI and automation on site operationsImproving interoperability and workflow integrationAdvancing diversity, accessibility, and inclusion in clinical trialsBuilding resilient and sustainable research programsEmerging trends shaping the next generation of clinical research sitesEpisode Highlights✔ Expert insights into the challenges and opportunities facing modern clinical research sites✔ Perspectives on AI, digital transformation, and technology-enabled clinical trials✔ Practical strategies for improving site sustainability and operational efficiency✔ A discussion on patient-centric trial design, accessibility, and engagement✔ A forward-looking vision for the future of clinical research and patient careSubscribe to the Life Science Insights Podcast for more conversations with industry leaders, innovators, and experts shaping the future of clinical research, biotechnology, and healthcare.#LifeScienceInsights #ClinicalResearch #ClinicalTrials #SCRS #JimmyBechtel #ResearchSites #SiteManagement #PatientCentricity #DecentralizedTrials #AIInHealthcare #DigitalHealth #Biotechnology #HealthcareInnovation #ClinicalOperations #FutureOfClinicalResearch

    E29 - The Future of Clinical Research Sites | Jimmy Bechtel (CSSO, SCRS) | Life Science Insights

  2. Jul 9

    E28 - Bridging Scientific Breakthroughs & Commercial Success | Mark Van Zee, Saku Biosciences

    In this episode of the Life Science Insights Podcast, we sit down with Mark Van Zee, Founder and CEO of Saku Biosciences, to explore the future of scalable biology and how innovations in cell line development are transforming modern biomanufacturing. Mark shares his journey from bioengineering research to entrepreneurship and explains why the greatest challenge facing biotechnology today is not scientific discovery—but scaling innovation to deliver real-world impact.From breakthrough PicoShell® technology to the future of automation, sustainable biomanufacturing, and next-generation cell engineering, this conversation examines how advanced technology platforms are accelerating drug development, improving manufacturing efficiency, reducing costs, and expanding global access to innovative therapies.Key Topics DiscussedMark Van Zee's journey from bioengineering research to founding Saku BiosciencesWhy biotechnology faces a scalability challenge rather than an R&D challengeUnderstanding PicoShell® technology and its applicationsAccelerating cell line development through advanced screening technologiesThe impact of high-performing producer cells on biomanufacturing efficiencyKey factors biopharma companies consider when evaluating new technology platformsThe role of automation and advanced screening in eliminating development bottlenecksStrengthening biomanufacturing supply chains through modern technologiesSustainable biotechnology and the importance of alternative feedstocksReducing downstream processing costs through improved cell engineeringChallenges and opportunities in scaling biotechnology innovationsBalancing scientific innovation with fundraising and commercializationLessons learned while building Saku BiosciencesThe future of scalable biology across healthcare, food, and industrial biotechnologyEpisode Highlights✔ Why scaling remains one of biotechnology's greatest challenges✔ How PicoShell® technology is transforming cell line development✔ The growing role of automation in modern biomanufacturing✔ Strategies for building more resilient and sustainable biotech supply chains✔ Insights into commercializing breakthrough biotechnology platforms✔ A forward-looking vision for scalable biology and its impact across healthcare and industrySubscribe to the Life Science Insights Podcast for more conversations with innovators, entrepreneurs, and industry leaders shaping the future of biotechnology, life sciences, and healthcare.#LifeScienceInsights #SakuBiosciences #Biotechnology #Biomanufacturing #CellLineDevelopment #Bioprocessing #Biopharma #SyntheticBiology #LifeSciences #HealthcareInnovation #Bioengineering #Automation #ScalableBiology #BiotechPodcast #DrugDevelopment

    E28 - Bridging Scientific Breakthroughs & Commercial Success | Mark Van Zee, Saku Biosciences

  3. Jul 9

    E27 - Accelerating Drug Development with AI | Dr. Raviv Pryluk, CEO & Co-Founder of PhaseV

    In this episode of the Life Science Insights Podcast, we sit down with Dr. Raviv Pryluk, CEO and Co-Founder of PhaseV, to explore how artificial intelligence and causal machine learning are transforming clinical development. Dr. Pryluk explains how AI-driven trial optimization is making clinical trials faster, smarter, and more efficient—while reducing costs, minimizing risk, and improving the probability of success.We discuss PhaseV's innovative approach to adaptive, causal, and data-driven clinical development, the growing role of AI in clinical decision-making, and how next-generation technologies are helping sponsors design more efficient, personalized, and successful clinical trials.Key Topics DiscussedUnderstanding adaptive, causal, and data-driven clinical developmentHow causal machine learning differs from traditional AI approachesDefining AI-driven clinical trial optimization in practical termsHow PhaseV's Trial Optimizer enhances trial efficiency while reducing costsBalancing statistical rigor with real-world clinical trial constraintsReal-world examples of AI-driven trial optimizationMajor inefficiencies in today's clinical trial ecosystemUsing AI and machine learning to de-risk drug developmentRegulatory perspectives on AI-enabled clinical trial designBuilding trust, transparency, and interpretability in AI-driven decision-makingAddressing data variability and bias across diverse patient populationsLeadership lessons from building and scaling an AI-driven healthcare companyBuilding multidisciplinary teams across AI, biology, and clinical researchThe future of clinical trials: smaller, faster, and more personalized studiesThe long-term impact of AI on the economics of drug developmentEpisode Highlights✔ A clear explanation of causal machine learning and why it matters✔ How AI is optimizing trial design, patient selection, and clinical outcomes✔ Strategies for reducing clinical trial costs, timelines, and development risk✔ The importance of explainable and trustworthy AI in clinical decision-making✔ Leadership insights from building and scaling an AI-first healthcare company✔ A forward-looking vision for the future of AI-powered clinical developmentSubscribe to the Life Science Insights Podcast for more conversations with innovators, researchers, and industry leaders advancing the future of biotechnology, life sciences, and healthcare.#LifeScienceInsights #PhaseV #ArtificialIntelligence #ClinicalTrials #DrugDevelopment #MachineLearning #CausalAI #ClinicalResearch #PrecisionMedicine #Biotechnology #HealthcareInnovation #DigitalHealth #LifeSciences #AIInHealthcare #BiotechPodcast

    E27 - Accelerating Drug Development with AI | Dr. Raviv Pryluk, CEO & Co-Founder of PhaseV

  4. Jul 9

    E26 - How Peptides Are Evolving Beyond Traditional Drugs | Karsten Eastman, CEO & Co-founder

    In this episode of the Life Science Insights Podcast, we sit down with Karsten Eastman, CEO and Co-founder of Sethera Therapeutics, to explore how innovative enzyme-based technologies are transforming drug discovery. Karsten shares the inspiration behind founding Sethera, the scientific challenges the company is addressing, and how its unique platform is enabling the discovery of next-generation peptide therapeutics for difficult-to-treat diseases.We discuss the power of enzymes in drug discovery, the promise of enzymatically constrained peptides, the role of AI and data in modern biotechnology, and the future of peptide-based medicines.Key Topics Discussed:The inspiration behind founding Sethera TherapeuticsThe unmet needs in drug discovery that Sethera aims to addressAn overview of Sethera's technology platform and missionWhat differentiates Sethera from other biotech companiesUnderstanding enzyme-enabled drug discovery in simple termsWhy enzymes are powerful tools for creating novel medicinesThe science and potential of enzymatically constrained peptidesAddressing hard-to-treat diseases and previously undruggable targetsDiscovering therapies for previously inaccessible biological targetsHow Sethera identifies, screens, and optimizes new moleculesThe role of data, AI, and machine learning in drug discoveryChallenges and lessons learned while building a biotechnology companyBalancing scientific innovation with business growth and executionBuilding high-performing, multidisciplinary biotech teamsEmerging trends shaping the future of biotechnology and drug discoveryThe future impact of peptide-based therapeutics on healthcareEpisode Highlights✔ The founding story behind Sethera Therapeutics✔ A simple explanation of enzyme-enabled drug discovery✔ Why constrained peptides represent an exciting new therapeutic class✔ How biotechnology is expanding the range of druggable targets✔ The growing role of AI, data, and advanced platforms in drug discovery✔ A vision for the future of precision medicine and patient careSubscribe to the Life Science Insights Podcast for more conversations with innovators and industry leaders shaping the future of biotechnology, life sciences, and healthcare.#LifeScienceInsights #SetheraTherapeutics #DrugDiscovery #Biotechnology #PeptideTherapeutics #Biotech #LifeSciences #PrecisionMedicine #DrugDevelopment #Enzymes #AIinBiotech #HealthcareInnovation #Biopharma #LifeSciencePodcast #futureofmedicine

    E26 - How Peptides Are Evolving Beyond Traditional Drugs | Karsten Eastman, CEO & Co-founder

  5. Jun 17

    E25 - Reimagining Medtech Innovation | Holly Coter T| Co-Founder, indieMedTech

    In this episode of the Life Science Insights Podcast, we explore the future of MedTech collaboration, innovation, and community-driven growth with , Co-Founder of and White Lamb Medtech Consulting.In a conversation about her journey building platforms that connect MedTech professionals, strengthen industry partnerships, and support meaningful collaboration across the healthcare ecosystem. With over a decade of experience in global medical devices and regulatory strategy, she shares deep insights into navigating complex regulatory landscapes and scaling innovation across regions. Key Topics DiscussedThe episode explores the founding vision behind indieMedTech and the industry gaps it aims to solve, along with the meaning of building a true “community” in MedTech. Holly discusses how regulatory expectations vary across global markets and how companies can successfully navigate these complexities.Additional themes include fostering authentic collaboration in a competitive industry, building successful MedTech partnerships, and avoiding common mistakes when scaling globally. The conversation also highlights barriers to cross-stakeholder collaboration and how ecosystem alignment can accelerate innovation.Episode HighlightsThe inspiration and purpose behind founding indieMedTechThe evolving definition of community in MedTechStrategies for global regulatory navigationBuilding trust and collaboration in a competitive ecosystemCommon scaling mistakes in MedTech companiesSkills required for the next generation of MedTech professionalsHow professionals can build visibility and credibilityThe role of digital transformation in enabling innovationLeadership lessons from building a global MedTech networkMeasuring success through both growth and community impact. The future of inclusive leadership in MedTechThe next 5–10 year outlook for MedTech ecosystemsAdvice for global expansion and cross-border innovationThe core message on collaboration driving MedTech progressThe episode closes with a reflection on the future of MedTech communities and how collaboration, shared learning, and ecosystem thinking will shape the next wave of healthcare innovation.

    E25 - Reimagining Medtech Innovation | Holly Coter T| Co-Founder, indieMedTech

  6. Apr 6

    E24 - Transforming Scientific Documents with AI | Levi S. Lian | CEO & Founder, Raycaster

    In this episode, we sit down with Levi S. Lian, CEO and Founder of Raycaster, to explore the critical evolution of document intelligence within the enterprise landscape. Drawing from a background that spans Stanford, Harvard Business School, and a deep-rooted family history in medicine, Levi shares his unique perspective on building AI-driven infrastructure that tackles one of the most persistent bottlenecks in modern business: the unstructured and complex document. The conversation centers on the shift from traditional OCR and simple automation toward true document reasoning. We examine why scientific and technical documents pose such a significant challenge for legacy systems and how Raycaster is enabling organizations to move beyond mere data extraction to achieve actionable insights. We take a closer look at the strategic hurdles of enterprise AI adoption, discussing the vital balance between rapid product innovation and the rigorous demands of data security, accuracy, and regulatory compliance. Listeners will gain a masterclass in the future of knowledge work and the ROI of modernizing document-heavy workflows. We discuss Levi’s journey as both a technical founder and an angel investor, offering insights into scaling AI infrastructure, overcoming misconceptions about machine intelligence, and the long-term risks facing industries that remain tethered to manual document processing.

    E24 - Transforming Scientific Documents with AI | Levi S. Lian | CEO & Founder, Raycaster

  7. Mar 23

    E23 - Building a Therapeutics Platform from the Ground Up | Dr. Stanley Lewis, CEO of A28 Therapeutics

    In this episode, we are joined by Dr. Stanley T. Lewis, MD, MPH, Founder and CEO of A28 Therapeutics, to trace his profound transition from physician-scientist to biotech entrepreneur. With a career rooted in translational medicine and clinical development, Dr. Lewis provides an expert perspective on the arduous journey of moving innovation from the laboratory bench to the patient’s bedside. We dive into his mission to redefine precision oncology through Targeted Oncolytic Peptides (TOPs)—a novel modality designed to treat cancer with surgical precision while prioritizing the patient’s quality of life. The conversation explores the strategic and scientific architecture required to build a therapeutics platform from scratch. We examine the lessons learned from Dr. Lewis’s previous success in bringing Trogarzo to market and how those cross-disciplinary insights from virology and infectious diseases are now being applied to solve unmet clinical needs in oncology. We take a closer look at the evolution of A28’s pipeline, discussing how the integration of biomarkers and advanced delivery systems is shaping the next generation of targeted cancer treatments. Listeners will gain a rare look at the human-centered side of biotech leadership. We discuss the complexities of navigating regulatory milestones and financing, the importance of maintaining scientific rigor under the pressure of patient urgency, and why empathy remains the most critical component of medical innovation. Whether you are a scientist, a founder, or a healthcare leader, this episode offers a roadmap for balancing high-stakes operational execution with a steadfast focus on the human impact of medicine.

    E23 - Building a Therapeutics Platform from the Ground Up | Dr. Stanley Lewis, CEO of A28 Therapeutics

  8. Mar 2

    E22 - Advancing the Future of Therapeutics | Ganesh Iyer, CEO & Founder, Opprtna Therapeutics

    In this episode, we sit down with Ganesh Iyer, CEO and Founder of Opprtna Therapeutics and Drug Discovery Partners, to explore the high-stakes world of deep science entrepreneurship. Ganesh shares the personal and professional motivations that led him to tackle some of medicine's most formidable challenges—neurodegeneration and cancer. We delve into the founding vision of Opprtna and its pursuit of a "premium" therapeutics platform that leverages the unique capabilities of aptamers to reach targets once considered undruggable. The conversation provides a technical yet accessible deep dive into aptamer-based modalities, comparing their precision and flexibility to traditional antibodies and small molecules. We examine the specific hurdles of Central Nervous System (CNS) targeting and the innovative delivery strategies required to cross the blood-brain barrier. Ganesh shares his expertise on translating early-stage preclinical discovery into clinical-ready assets, emphasizing the necessity of scientific rigor and strategic target selection in a competitive biotech landscape. Listeners will gain a comprehensive look at the business of drug discovery, from navigating complex funding environments to building multidisciplinary teams that can scale. We discuss the balance between maintaining robust in-house capabilities and leveraging external partnerships to accelerate innovation. Whether you are an aspiring scientist-founder or a seasoned industry leader, this episode offers vital insights into the leadership, culture, and breakthroughs defining the next frontier of precision medicine.

    E22 - Advancing the Future of Therapeutics | Ganesh Iyer, CEO & Founder, Opprtna Therapeutics
See All (29)

About

Welcome to Life Science Insights360, your go-to source for deep conversations with the innovators shaping the future of healthcare, biotech, and life sciences. Hosted by Senthil Karunanith, each episode dives into cutting-edge topics—from translational omics and therapeutic breakthroughs to strategic data insights, quality management, and real-world challenges in pharma, medtech, and diagnostics . Expect dynamic interviews with industry leaders—CEOs, scientists, strategists—who share real-world case studies and forward-thinking visions.

Information